Paul Beresford, PhD, Biodesix, discusses utilizing VeriStrat technology to select which patients may benefit from immunotherapies.

VeriStrat is a serum proteomic test that helps physicians select treatment. It is primarily marketed for use in advanced non-small cell lung cancer patients; however, it can be applied to multiple tumor types, said Beresford.

Early stage feasibility studies show that the VeriStrat platform may be able to identify which patients will benefit from immunotherapies, including checkpoint inhibitors.

Biodesix is also involved in generating new classifiers through their proteomic platform, which is uniquely suited to addressing questions regarding the impact of immunotherapies on the tumor, says Beresford.

Paul Beresford, PhD

Articles

Beresford Discusses Using VeriStrat With Immunotherapies